SORL1 is a unique sorting receptor for directing APP to a non-amyloidogenic pathway, and the brain concentrations of SORL1 are inversely correlated with Aβ levels in mouse models and AD patients, suggesting that increasing expression of SORL1 receptor could be a novel therapeutic strategy for reducing the amount of amyloidogenic products. Here, APP is linked to Alzheimer disease.